ZyVersa enters warrant exercise inducement; expected gross proceeds ~$2.05M

ZyVersa Therapeutics, Inc.

Existing Series A-2 and A-3 warrants with $1 exercise price reduced to $0.67; holder exercises for cash.
Company issues new Series A-4 warrants to purchase 200% of exercised shares, $0.67 exercise price, 5-year term.
If all warrants exercised, gross proceeds ~$2.05 million; proceeds for working capital.
Issuance of inducement warrant shares subject to stockholder approval; registration statement to be filed by August 8, 2025.
AGP acts as financial advisor, receiving 6.5% cash fee of aggregate gross proceeds.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.